The EU HTA Regulation has been in place for almost two years, EUnetHTA21 period ends in September and the first central clinical assessments are coming closer. This will dramatically change the way we work in general, and conduct market access in the EEA realm. The full scope of long term changes is hard to predict, but the first parts, including the HTA regulation and EUnetHTA21 deliverables, are already there. With his extensive experience working in multiple working groups and EU trade associations on the latest EU legislations, and formerly running Global Market Access at MEDAC, in this presentation Thomas Grub will:
- Provide an extensive overview of what the new HTA regulation is, and isn’t.
- How it will affect the industry, and why we shouldn’t panic
- What do we need to know to change our internal processes?
- Inform about latest changes from EU Commission and HTA Coordination Group
&nsbp;
